ProNAi Therapeutics Company Profile (NASDAQ:DNAI)

Analyst Ratings

Consensus Ratings for ProNAi Therapeutics (NASDAQ:DNAI) (?)
Ratings Breakdown: 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $19.88 (883.91% upside)

Analysts' Ratings History for ProNAi Therapeutics (NASDAQ:DNAI)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016WedbushDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016SunTrust Banks Inc.DowngradeBuy -> Neutral$25.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupDowngradeBuy -> Hold$22.00 -> $4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Bank of America Corp.Initiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for ProNAi Therapeutics (NASDAQ:DNAI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/19/2016        
5/10/2016Q1($0.42)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.58)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.48)($11.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/21/2015Q215($104.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ProNAi Therapeutics (NASDAQ:DNAI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.54)($0.39)($0.44)
Q2 20163($0.41)($0.37)($0.38)
Q3 20163($0.33)($0.31)($0.32)
Q4 20163($0.31)($0.23)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ProNAi Therapeutics (NASDAQ:DNAI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ProNAi Therapeutics (NASDAQ:DNAI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/22/2016Wendy ChapmanSVPSell3,000$7.01$21,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Wendy ChapmanSVPSell3,000$7.06$21,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Wendi RodiguezainsiderSell3,000$9.86$29,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Wendy ChapmanSVPSell5,000$9.39$46,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Nicholas GloverCEOSell5,000$10.04$50,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Chandra D. LovejoySVPSell20,973$11.29$236,785.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015Orbimed Advisors LlcDirectorBuy175,000$17.00$2,975,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015Vivo Ventures Vii, LlcInsiderBuy220,000$17.00$3,740,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ProNAi Therapeutics (NASDAQ:DNAI)
DateHeadline
07/23/16 07:46 AMAre Analysts Bearish ProNAi Therapeutics Inc (NASDAQ:DNAI) After Last Week? - Consumer Eagle
07/21/16 09:07 PMProNAi Therapeutics Inc (NASDAQ:DNAI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:16 AMEarnings Focus and Crowd Sourced Sentiment Review for ProNAi Therapeutics Inc (NASDAQ:DNAI) - TGP
07/20/16 08:16 AMEquity Roundup: Stock Performance Focus on ProNAi Therapeutics Inc (NASDAQ:DNAI) - Press Telegraph
07/20/16 08:16 AMBroker Outlook For ProNAi Therapeutics, Inc. (DNAI) - Fiscal Standard
07/19/16 09:47 AMAnalysts Suggestion Alert: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Street Updates
07/18/16 03:47 PMProNAi Therapeutics Inc (NASDAQ:DNAI)'s Company Shares Decreased 2.43% After Low Volatility - Consumer Eagle
07/17/16 08:10 AMProNAi Therapeutics, Inc. (DNAI) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 03:32 PMProNAi Therapeutics Inc Stock Momentum Hits Extreme Weakness - CML News
07/15/16 02:39 PMNew Broker Ratings For ProNAi Therapeutics, Inc. (DNAI) - FTSE News
07/15/16 07:00 AMPronai Therapeutics Incorporated (NASDAQ:DNAI) Shorted Shares Increased 9.52% After Market Selling - Press Telegraph
07/15/16 07:00 AMWere Analysts Bearish ProNAi Therapeutics Inc (NASDAQ:DNAI) This Week? - Consumer Eagle
07/14/16 05:19 AMAnalyst Target and Average Rating Watch: ProNAi Therapeutics Inc (NASDAQ:DNAI) - Press Telegraph
07/13/16 08:35 AMProNAi Therapeutics Inc (NASDAQ:DNAI) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/10/16 08:10 AMPronai Therapeutics Incorporated (NASDAQ:DNAI) Shorted Shares Increased By 9.52% - Engelwood Daily
07/07/16 08:51 PMCompany Stock Focus for ProNAi Therapeutics Inc (NASDAQ:DNAI): Which Way Will Shares Head? - Press Telegraph
07/06/16 03:43 PMProNAi Therapeutics, Inc. (DNAI) Current Analyst Ratings - Fiscal Standard
07/05/16 08:25 AMProNAi Therapeutics, Inc. (DNAI) Updated Price Targets - FTSE News
06/30/16 03:52 PMRecently Issued Stock Ratings For ProNAi Therapeutics, Inc. (DNAI) - Fiscal Standard
06/28/16 03:35 PMBroker Outlook For The Week Ahead ProNAi Therapeutics, Inc. (DNAI) - Fiscal Standard
06/26/16 03:16 PMPronai Therapeutics Incorporated (NASDAQ:DNAI) Short Interest Increased By 9.52% - Press Telegraph
06/24/16 10:24 AMPrice Target Update on ProNAi Therapeutics (NASDAQ:DNAI) - Trade Calls
06/23/16 08:39 PMProNAi Therapeutics Inc (NASDAQ:DNAI) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 02:34 PMInvestor News: Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over potential Violations of Securities Laws - GroundReport
06/22/16 03:47 PMProNAi Therapeutics (NASDAQ:DNAI) Analyst Rating Consensus - TheFounders Daily
06/22/16 08:20 AMInvestor News: Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over potential Violations of Securities Laws
06/21/16 03:28 PMPRONAI THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/21/16 03:17 PMPRONAI THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 09:53 AMThis Weeks Broker Views For ProNAi Therapeutics, Inc. (DNAI) - Fiscal Standard
06/17/16 08:55 AMLatest ProNAi Therapeutics, Inc. (NASDAQ:DNAI) Target Price Suggests Stock Is Worth $11.63/Share - iStreetWire
06/17/16 08:55 AMAnalyst Recommendations: Liberty Ventures (NASDAQ:LVNTA), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/15/16 03:44 PMTwo Movers inside Analysts Radar: GLOBAL BLOOD THERAPEUTICS, INC. (NASDAQ:GBT) , ProNAi Therapeutics ... - Street Updates
06/15/16 03:44 PMAnalyst Recommended Stocks: Duke Realty Corporation (NYSE:DRE), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/15/16 03:44 PMStock's Earnings Analysis: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), Prospect Capital Corporation (NASDAQ:PSEC) - Beacon Chronicle
06/14/16 03:31 PMInvestor Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over Possible Violations of Securities Laws
06/13/16 08:42 AMBiotech New Lows: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), Chimerix, Inc. (NASDAQ:CMRX), ImmunoGen, Inc ... - KC Register
06/13/16 08:42 AMHot Stock under Consideration: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/10/16 10:53 AMWeekly roundup: Get your baseball tickets ... late | Depositing money at Starbucks | Apple’s coming tweaks -
06/10/16 08:46 AMPreview of Analysts Recommendation: Cellectar Biosciences, Inc. (NASDAQ:CLRB) , ProNAi Therapeutics, Inc ... - Street Updates
06/10/16 08:46 AMBest Stocks for Investors: Baidu, Inc. (NASDAQ:BIDU), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/09/16 09:43 PMStock under Analyst' Radar: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/09/16 10:57 AMTwo Buzzers within Analysts Radar: Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) , ProNAi Therapeutics, Inc ... - Street Updates
06/08/16 08:27 PMAnalysts Suggestion Alert: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Street Updates
06/08/16 08:27 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ProNAi Therapeutics, Inc ... - PR Newswire (press release)
06/08/16 02:34 PMStock Analysis review: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/08/16 02:12 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ProNAi Therapeutics, Inc. (DNAI) - [PR Newswire] - NEW YORK, June 8, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ProNAi Therapeutics, Inc. ...
06/08/16 09:21 AMPRONAI THERAPEUTICS INC. (NASDAQ:DNAI) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:46 PMProNAi Therapeutics Inc. (DNAI) Plunged After Development Of PNT2258 Suspended - RTT News
06/07/16 10:17 AMAnalyst Ratings on: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), EMC Corporation (NYSE:EMC) - Beacon Chronicle
06/07/16 10:17 AMTwo Buzzers within Analysts Radar: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates

Social

About ProNAi Therapeutics

ProNAi Therapeutics logoProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology. It has conducted over two clinical trials for PNT2258, which include a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DNAI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.05
  • 50 Day Moving Average: $2.15
  • 200 Day Moving Average: $5.82
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $60.95M
  • Current Year EPS Consensus Estimate: $-1.33 EPS
  • Next Year EPS Consensus Estimate: $-1.04 EPS
Additional Links:
ProNAi Therapeutics (NASDAQ:DNAI) Chart for Sunday, July, 24, 2016